LENS Back In Focus, NVTR Rides High, BTAI For The Long Haul, CHRS Resubmits BLA

21:03 EDT 3 May 2018 | RTTNews

Coherus BioSciences has re-submitted its biologics license application for CHS-1701, a biosimilar candidate for Amgen Inc's blockbuster treatment, Neulasta.

More From BioPortfolio on "LENS Back In Focus, NVTR Rides High, BTAI For The Long Haul, CHRS Resubmits BLA"